Quick Answer
Janux Therapeutics, Inc. reported Common Stock Shares Outstanding of 60.38 million shares for the year ending 2025.
- Janux Therapeutics, Inc. showed an increase of +2.2% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Janux Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: 41.09 million shares | Q3 2021: 41.17 million shares | Q1 2022: 41.39 million shares | Q2 2022: 41.50 million shares | Q3 2022: 41.55 million shares | Q1 2023: 41.80 million shares | Q2 2023: 41.87 million shares | Q3 2023: 46.15 million shares | Q1 2024: 51.84 million shares | Q2 2024: 52.16 million shares | Q3 2024: 52.34 million shares | Q1 2025: 59.17 million shares | Q2 2025: 59.30 million shares | Q3 2025: 60.12 million shares.
- Over the full 6 years of available data (2020 to 2025), Janux Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 5,669.6%.
- Historical annual values: Fiscal year 2025: 60.38 million shares | Fiscal year 2024: 59.06 million shares | Fiscal year 2023: 46.25 million shares | Fiscal year 2022: 41.62 million shares | Fiscal year 2021: 41.24 million shares | Fiscal year 2020: 1.05 million shares.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: